Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

liver solid financial results and to advance our late-stage pipeline, with four regulatory filings completed this year alone," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We are successfully executing our strategy which will enable us to return to growth after 2014 by bringing to the market new medicines that make a real difference for patients."

"We remain committed to our innovation strategy and believe it will drive growth and expand margins post-2014," added Derica Rice, Lilly executive vice president, global services and chief financial officer. "We will also return substantial cash to shareholders by maintaining our dividend at least at its current level and by repurchasing shares under our recently-authorized $5 billion program."

Key Events Over the Last Three Months

  • Dulaglutide was submitted for regulatory review in both the U.S. and Europe as a potential treatment for type 2 diabetes.
  • The U.S. rolling submission was completed for ramucirumab as a single-agent treatment for patients with advanced gastric cancer who have had disease progression after initial chemotherapy. A submission for ramucirumab for the same indication was also made in Europe.
  • Top-line results were announced from two global Phase III studies of ramucirumab. In the first study, ramucirumab, in combination with paclitaxel in patients with advanced gastric cancer, met its primary endpoint of improved overall survival and a secondary endpoint of improved progression-free survival. A second study of ramucirumab in women with locally recurrent or metastatic breast cancer did not meet its primary endpoint of progression-free survival.
  • A recently completed Phase III study for necitumumab met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer experienced increased overall survival when administered necitumumab in combination with gemcitabine and
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
    2. Lilly Declares Fourth-Quarter 2013 Dividend
    3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
    4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
    5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
    6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
    7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
    8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
    9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
    10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
    11. Lilly Reports Second-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced ... 9 th Annual Global Pharma Manufacturing Summit ... 8-9 th . The Global Pharma Manufacturing Summit ... small molecule and biologic pharmaceutical manufacturing. The conference ... today,s manufacturers face, such as the increasing pressure ...
    (Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery is ... media, both for the promise of improved outcomes ... quick deployment of surgical robots and market pressures ... facilities to evaluate their robotic surgery training programs ... team.    ECRI Institute ( www.ecri.org ...
    (Date:8/28/2014)... THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ ... the submission of a Biologics License Application (BLA) to ... seeking approval for the treatment of high cholesterol. Evolocumab ... proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that ... (LDL-C), or "bad" cholesterol, from the blood. 1 ...
    Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
    ... Mass. , July 26 The Exergen ... nationwide that stock the Exergen TemporalScanner™, according to data ... of all types of thermometers, including national brands and ... found Exergen came out on top. Exergen,s retail unit ...
    ... , NEWARK, Del. and GRONINGEN, Netherlands ... a leading full-service GLP/GCP-compliant contract research organization providing testing ... announced the completion of its acquisition of Xendo Drug ... .  XDD, a European contract research organization (CRO), will ...
    Cached Medicine Technology:Exergen TemporalScanner Thermometer Best Selling Brand at Retailers 2QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4
    (Date:8/28/2014)... Mateo, CA (PRWEB) August 28, 2014 ... that the MRI Technology program is re-accredited for the ... of Magnetic Resonance Imaging Technologists (ARMRIT). , “We ... We are constantly improving our program to make sure ... is a lot of interest in MRI field nowadays ...
    (Date:8/28/2014)... Did they fall from trees and learn to flap their ... ground and pump their "arms" to get aloft? , The ... a new University of California, Berkeley, study provides a new ... maneuver in midair, a talent that could have helped their ... , The study looked at how baby birds, in this ...
    (Date:8/28/2014)... Data from the American Hospital Association’s 2013 Annual ... a basic electronic health record (EHR) system, more advanced ... challenge. , This data is featured in an ... , and is co-authored by Peter Kralovec, executive director ... as Chantal Worzala, director for policy at the AHA. ...
    (Date:8/28/2014)... Ariz. Aug. 28, 2014 In 2012, ... million in grants for two groundbreaking brain cancer ... (TGen). One of those projects has officially received ... San Francisco, which means patient enrollment for the ... project, "Genomics Enabled Medicine in Glioblastoma Trial," TGen ...
    (Date:8/28/2014)... CORAL GABLES, Fla (Aug. 26, 2014)-- Cigarette smoking ... the Centers for Disease Control and Protection. It,s ... order to overcome this addiction, many people resort ... literature review study by researchers at the University ... nicotine found in cigarette substitutes could be harmful ...
    Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3
    ... In a research paper presented at the 113th Annual ... that it is possible to regulate the incidence of ... the computer to stay connected with people.,The data regarding ... of the latest wave of an ongoing longitudinal study ...
    ... was extracted from the Herb Black Cohosh [An Indian herb], ... [HRT]. Doctors say herb used by American Indians for ... for women going through menopause. As synthetic HRT use is ... , ,Professor John Eden from Sydney’s Royal Hospital for ...
    ... hours for treatment for heart attacks, may be more ... blood flow, said a research // findings in the ... blood flow to an organ or tissue) with either ... coronary intervention (PCI; procedures such as angioplasty in which ...
    ... how neurons fire in a part of the brain ... of schizophrenia and Alzheimer's disease. // , ,A ... nervous system has been the focus of the research. ... them where they're supposed to go. In adult mice, ...
    ... disorders like rheumatoid arthritis may be reduced by ... carrots and sweetcorn. //, ,Vitamin C and ... in brightly-coloured fruit and veg, may act as ... damage and inflammation. ,The levels of intake ...
    ... Researchers from University of Michigan had identified a protein ... sensori-neural hearing loss or AISNHL.//, ,In the August ... Neck Surgery, researchers reports results from a study of ... Pennsylvania and Indiana, and 20 people with normal hearing. ...
    Cached Medicine News:Health News:Heart Attack Patients Reaching Hospital During Off-Hours Have Increased Risk Of Death 2Health News:Learning process to be regulated by altering brain protein 2
    ... Introducing the new PRONEB® ULTRA compressor. ... treatment time while delivering more medication to ... PARI LC PLUS® or PARI LC STAR® ... are optimized for inhalation and retention into ...
    ... Compressed Air., ,Allied Healthcares Timeter® PCS 414 ... other air compressors that you may wonder if ... PCS 414 features a durable, mar-resistant steel case ... unit weighs only 26.5 pounds. The PCS 414 ...
    ... DC powered compressor nebulizer system available. ... to take nebulizer treatments away from ... the included AC power adapter or ... The integral reusable jet nebulizer kit ...
    The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
    Medicine Products: